New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 28, 2014
07:17 EDTHZNPHorizon Pharma price target raised to $25 from $18 at Stifel
Stifel increased its price target on Horizon as the firm thinks that the company's acquisition of Vidara has left it in "ideal position" to become profitable and meet its revenue and EBITDA guidance. The firm thinks the company's drug portfolio is poised to perform well, and keeps a Buy rating on the shares.
News For HZNP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 18, 2014
16:12 EDTHZNPHorizon Pharma reports positive effect of RAYOS in reducing joint stiffness
Subscribe for More Information
November 14, 2014
08:06 EDTHZNPHorizon Pharma 11.66M share Secondary priced at $12.05
Subscribe for More Information
November 13, 2014
14:56 EDTHZNPHorizon Pharma says Watson Labs filed ANDA for generic PENNSAID
Subscribe for More Information
07:06 EDTHZNPHorizon Pharma files to sell 11.66M shares for existing holders
Horizon Pharma announced a proposed underwritten secondary offering of 11.66M of its ordinary shares held by certain of its existing shareholders. Morgan Stanley, Citigroup, Cowen and Jefferies are acting as joint book-running managers for this offering. JMP Securities is acting as financial advisor for this offering.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use